Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8206982 | 0.95 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL6157010 | 0.94 | ITGB3 (0.82) | ITGB3ITGA2B | |
| SCHEMBL7358243 | 0.94 | ITGB3 (0.82) | ITGB3ITGA2B | |
| SCHEMBL6157600 | 0.94 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7293205 | 0.94 | ITGB3 (0.76) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL7026781 | 0.93 | ITGB3 (0.81) | ITGB3ITGA2B | |
| SCHEMBL6157611 | 0.93 | ITGB3 (0.81) | ITGB3ITGA2B | |
| SCHEMBL7284135 | 0.93 | ITGB3 (0.78) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL7335225 | 0.93 | ITGB3 (0.75) | ITGB3ITGA2B | |
| SCHEMBL6159763 | 0.92 | ITGB3 (1.00) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187249-A1 | An aqueous solution of a physiologically active substance which may have a substituent and which has an amidino group, the solution having a pH > 2 and -/< than 4; storage stability; parental injections; 2-[4-[((3S)-1-acetoimidoyl-3-pyrrolidinyl)oxy]phenyl] -3-(7-amidino-2-naphthyl)propionic acid; kits | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1504755-A1 | LYOPHILIZATION PRODUCT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-0950407-B1 | The use of a GP IIb/IIIa antagonist for the manufacture of a medicament suitable for transdermal application by iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-0822931-B1 | PIPERAZINONES USEFUL AS INHIBITORS OF PLATELET AGGREGATION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-6322550-B2 | Method for transdermal administration of GP IIb/IIIa antagonist | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-11-27 | — | — | US | disclosed |
| US-20010018568-A1 | METHOD FOR TRANSDERMAL ADMINISTRATION OF GP IIB/IIIA ANTAGONIST | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-08-30 | — | — | US | disclosed |
| US-6020334-A | Piperazinones, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0950407-A1 | Method for transdermal administration of GP IIb/IIIa antagonist | Takeda Chemical Industries, Ltd. (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-5935963-A | (4-GUANIDINOBENZOYLAMINO)ACETYL-3-(3-(4-GUANIDINOBENZOYLAMINO) PROPYL)-2-OXOPIPERAZINE-1-ACETIC ACID OR A SALT; CONTROLLING OR INHIBITING CELL-ADHESION; PLATELET ANTIAGGREGATION WITHOUT LONG HEMORRHAGING; ANTIICHEMIC AGENTS; ANGINA PECTORIS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1999-08-10 | — | — | US | disclosed |
| US-5888531-A | ACTIVE MATERIAL STABILIZED WITH DISACCHARIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| US-5876756-A | SUSTAINED RELEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-02 | — | — | US | disclosed |
| EP-0822931-A1 | PIPERAZINONES USEFUL AS INHIBITORS OF PLATELET AGGREGATION | Takeda Chemical Industries, Ltd. (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0750913-A2 | Disaccharide containing freeze-dried preparation for pharmaceutical use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996033982-A1 | PIPERAZINONES USEFUL AS INHIBITORS OF PLATELET AGGREGATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187249-A1 | An aqueous solution of a physiologically active substance which may have a substituent and which has an amidino group, the solution having a pH > 2 and -/< than 4; storage stability; parental injections; 2-[4-[((3S)-1-acetoimidoyl-3-pyrrolidinyl)oxy]phenyl] -3-(7-amidino-2-naphthyl)propionic acid; kits | NGLY1, IDE, NPPA | ITGB3 3735/4885ITGA2B 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.